Harvest Fund Management Co. Ltd Sells 508 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Harvest Fund Management Co. Ltd decreased its position in United Therapeutics Co. (NASDAQ:UTHRFree Report) by 43.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 672 shares of the biotechnology company’s stock after selling 508 shares during the quarter. Harvest Fund Management Co. Ltd’s holdings in United Therapeutics were worth $241,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of UTHR. ClariVest Asset Management LLC lifted its position in United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 42 shares during the last quarter. V Square Quantitative Management LLC acquired a new position in shares of United Therapeutics during the 2nd quarter worth about $30,000. Innealta Capital LLC bought a new stake in United Therapeutics during the 2nd quarter valued at approximately $33,000. USA Financial Formulas acquired a new stake in United Therapeutics in the 3rd quarter valued at approximately $33,000. Finally, Capital Performance Advisors LLP bought a new position in United Therapeutics in the 3rd quarter worth approximately $82,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on UTHR. Bank of America reduced their price objective on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research report on Thursday, August 1st. Wells Fargo & Company raised their price target on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 20th. The Goldman Sachs Group upped their price objective on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. Jefferies Financial Group boosted their price target on United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. Finally, Argus raised their price objective on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $370.86.

Check Out Our Latest Report on United Therapeutics

Insider Activity

In related news, COO Michael Benkowitz sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $401.44, for a total value of $6,021,600.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares of the company’s stock, valued at $1,034,510.88. This trade represents a 85.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO James Edgemond sold 7,785 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the completion of the transaction, the chief financial officer now owns 2,615 shares of the company’s stock, valued at $947,597.55. This trade represents a 74.86 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 117,227 shares of company stock worth $43,671,320. 11.90% of the stock is owned by corporate insiders.

United Therapeutics Trading Up 2.3 %

Shares of United Therapeutics stock opened at $377.00 on Wednesday. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $417.82. The firm’s 50-day moving average price is $365.54 and its two-hundred day moving average price is $333.04. The stock has a market capitalization of $16.83 billion, a price-to-earnings ratio of 16.56, a P/E/G ratio of 1.07 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHRGet Free Report) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business’s revenue was up 22.9% on a year-over-year basis. During the same period last year, the firm posted $5.38 EPS. As a group, equities research analysts predict that United Therapeutics Co. will post 25.22 EPS for the current year.

About United Therapeutics

(Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

See Also

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.